Recommendations for the Use of Lyme Disease Vaccine: Recommendations of the211 Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality 211 Weekly Report, Vol.48, No. RR-7, June 4, 1999

摘要

This report provides recommendations for use of a newly developed recombinant211u001eouter-surface protein A (rOspA) Lyme disease vaccine (LYMErix, TM SmithKline 211u001eBeecham Pharmaceuticals) for persons aged 15-70 years in the United States. The 211u001epurpose of these recommendations is to provide health-care providers, public 211u001ehealth authorities, and the public with guidance regarding the risk for acquiring 211u001eLyme disease and the role of vaccination as an adjunct to preventing Lyme 211u001edisease. The Advisory Committee on Immunization Practices recommends that 211u001edecisions regarding vaccine use be made on the basis of assessment of individual 211u001erisk, taking into account both geographic risk and a persons activities and 211u001ebehaviors relating to tick exposure.